L N Leite1, N A Gonzaga1, D P C Tirapelli2, L F Tirapelli2, C R Tirapelli3. 1. Programa de Pós-Graduação em Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil. 2. Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil. 3. Laboratório de Farmacologia, Departamento de Enfermagem Psiquiátrica e Ciências Humanas, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
Abstract
The aim of the present study was to determine the mechanisms underlying the relaxant effect of adrenomedullin (AM) in rat cavernosal smooth muscle (CSM) and the expression of AM system components in this tissue. Functional assays using standard muscle bath procedures were performed in CSM isolated from male Wistar rats. Protein and mRNA levels of pre-pro-AM, calcitonin receptor-like receptor (CRLR), and Subtypes 1, 2 and 3 of the receptor activity-modifying protein (RAMP) family were assessed by Western immunoblotting and quantitative real-time polymerase chain reaction, respectively. Nitrate and 6-keto-prostaglandin F(1α) (6-keto-PGF(1α); a stable product of prostacyclin) levels were determined using commercially available kits. Protein and mRNA of AM, CRLR, and RAMP 1, -2, and -3 were detected in rat CSM. Immunohistochemical assays demonstrated that AM and CRLR were expressed in rat CSM. AM relaxed CSM strips in a concentration-dependent manner. AM(22-52), a selective antagonist for AM receptors, reduced the relaxation induced by AM. Conversely, CGRP(8-37), a selective antagonist for calcitonin gene-related peptide receptors, did not affect AM-induced relaxation. Preincubation of CSM strips with N(G)-nitro-L-arginine-methyl-ester (L-NAME, nitric oxide synthase inhibitor), 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, quanylyl cyclase inhibitor), Rp-8-Br-PET-cGMPS (cGMP-dependent protein kinase inhibitor), SC560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole, selective cyclooxygenase-1 inhibitor], and 4-aminopyridine (voltage-dependent K(+) channel blocker) reduced AM-induced relaxation. On the other hand, 7-nitroindazole (selective neuronal nitric oxide synthase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), H89 (protein kinase A inhibitor), SQ22536 [9-(tetrahydro-2-furanyl)-9H-purin-6-amine, adenylate cyclase inhibitor], glibenclamide (selective blocker of ATP-sensitive K(+) channels), and apamin (Ca(2+)-activated channel blocker) did not affect AM-induced relaxation. AM increased nitrate levels and 6-keto-PGF1α in rat CSM. The major new contribution of this research is that it demonstrated expression of AM and its receptor in rat CSM. Moreover, we provided evidence that AM-induced relaxation in this tissue is mediated by AM receptors by a mechanism that involves the nitric oxide-cGMP pathway, a vasodilator prostanoid, and the opening of voltage-dependent K(+) channels.
The aim of the present study was to determine the mechanisms underlying the relaxant effect of adrenomedullin (AM) in rat cavernosal smooth muscle (CSM) and the expression of AM system components in this tissue. Functional assays using standard muscle bath procedures were performed in CSM isolated from male Wistar rats. Protein and mRNA levels of pre-pro-AM, calcitonin receptor-like receptor (CRLR), and Subtypes 1, 2 and 3 of the receptor activity-modifying protein (RAMP) family were assessed by Western immunoblotting and quantitative real-time polymerase chain reaction, respectively. Nitrate and 6-keto-prostaglandin F(1α) (6-keto-PGF(1α); a stable product of prostacyclin) levels were determined using commercially available kits. Protein and mRNA of AM, CRLR, and RAMP 1, -2, and -3 were detected in rat CSM. Immunohistochemical assays demonstrated that AM and CRLR were expressed in rat CSM. AM relaxed CSM strips in a concentration-dependent manner. AM(22-52), a selective antagonist for AM receptors, reduced the relaxation induced by AM. Conversely, CGRP(8-37), a selective antagonist for calcitonin gene-related peptide receptors, did not affect AM-induced relaxation. Preincubation of CSM strips with N(G)-nitro-L-arginine-methyl-ester (L-NAME, nitric oxide synthase inhibitor), 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, quanylyl cyclase inhibitor), Rp-8-Br-PET-cGMPS (cGMP-dependent protein kinase inhibitor), SC560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole, selective cyclooxygenase-1 inhibitor], and 4-aminopyridine (voltage-dependent K(+) channel blocker) reduced AM-induced relaxation. On the other hand, 7-nitroindazole (selective neuronal nitric oxide synthase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), H89 (protein kinase A inhibitor), SQ22536 [9-(tetrahydro-2-furanyl)-9H-purin-6-amine, adenylate cyclase inhibitor], glibenclamide (selective blocker of ATP-sensitive K(+) channels), and apamin (Ca(2+)-activated channel blocker) did not affect AM-induced relaxation. AM increased nitrate levels and 6-keto-PGF1α in rat CSM. The major new contribution of this research is that it demonstrated expression of AM and its receptor in rat CSM. Moreover, we provided evidence that AM-induced relaxation in this tissue is mediated by AM receptors by a mechanism that involves the nitric oxide-cGMP pathway, a vasodilator prostanoid, and the opening of voltage-dependent K(+) channels.
The initiation and maintenance of penile erection is caused by relaxation of the blood
vessels in the cavernosal smooth muscle (CSM), which results in an increased blood flow
into the trabecular spaces of the corpora cavernosa (1). The control of CSM tone is mainly mediated by the adrenergic,
cholinergic, and nonadrenergic, noncholinergic (NANC) systems (2). Noradrenaline, released from sympathetic nerves, induces
contraction of penile CSM while parasympathetic innervations mediate smooth muscle
relaxation in the trabecular network and cavernosal arterial venous bed (3). Nitric oxide (NO) released from NANC nerve
endings and from the vascular endothelium is considered the most important mediator of
CSM relaxation (4). Release of
endothelium-derived NO is regulated by several factors, including vasodilator substances
such as adrenomedullin (AM), which has been demonstrated to play a role as a modulator
of erectile function (5-7).AM consists of a 52-amino acid peptide, initially isolated from humanpheochromocytoma
cells, that displays vasorelaxant and hypotensive actions (8). AM has a ring structure formed by a disulfide bond and an
amidated carboxyl terminal, and belongs to a family of peptides that include amylin and
calcitonin gene-related peptide (CGRP) (8). In
the vasculature, the relaxant response induced by AM is mediated by the
seven-transmembrane G protein-coupled calcitonin receptor-like receptor (CRLR), which
coassembles with Subtypes 2 and 3 of the receptor activity-modifying protein (RAMP)
family, thus forming a receptor-coreceptor system (9,10). Although the vasodilator effect
of AM in different blood vessels is well characterized (10), few reports have described the effect of AM in CSM relaxation. However,
it has been reported that intracavernosal injections of AM increased cavernosal pressure
and penile length in cats (5). This response was
not mediated by CGRP receptors and did not involve NO generation or the opening of
K+ channels (5,6). In anesthetized rats, intracavernosal
administration of AM resulted in increased cavernous pressure and penile erection, which
was attenuated by inhibitors of the NO-cGMP pathway (7). The relaxation induced by AM in isolated rabbit CSM strips does not
involve NO, vasodilator prostanoids, or the opening of K+ channels (11). Finally, AM is localized in human endothelial
cells of cavernous vessels, where it may contribute to penile erection (12). These findings imply that AM is a modulator of
CSM tone and suggest that AM might potentiate erectile function. Moreover, based on the
above-mentioned observations, it is possible to conclude that the mechanism by which AM
induces vasorelaxation or erection varies with species, vascular bed studied, and
experimental procedure employed.The AM system has been postulated to have a cardioprotective role in a wide range of
diseases (13). Cardiovascular diseases are often
associated with erectile dysfunction (ED) (14),
and, in this case, increased levels of AM may play a compensatory role for ED. Isolated
CSM is a useful model for the study of penile erectile responses and ED (15,16). Thus,
the study of physiological expression and function of AM receptors in CSM may provide
valuable information on the contribution of AM to CSM tone. The effect of AM on
cavernous pressure and penile erection has been previously evaluated in anesthetized
rats using intracavernous pressure measurements (7). However, to the best of our knowledge, there are no reports describing
the receptors involved in AM-induced relaxation of rat CSM or the detailed mechanisms
underlying such a response. The aims of the present study were to attempt a functional
characterization of the AM receptors in rat CSM and to investigate the mechanisms
underlying AM-induced relaxation in this tissue. In addition, quantitative real-time
polymerase chain reaction (qRT-PCR), Western immunoblotting, and immunohistochemical
assays were performed to verify expression of AM, CRLR, and RAMP1, -2, and -3 in rat
CSM.
Material and Methods
Animals
Male Wistar rats weighing 250-300 g (50-70 days of age) were housed under standard
laboratory conditions with free access to food and water. The housing conditions and
experimental protocols were approved by the Animal Ethics Committee of the
Universidade de São Paulo, Campus of Ribeirão Preto, Brazil (Protocol
#10.1.1293.53.4). The animals were anesthetized with isoflurane
[2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane] and killed by aortic
exsanguination. CSM was removed for functional assays, Western immunoblotting,
qRT-PCR, and immunohistochemical experiments.
qRT-PCR
Total cellular RNA was extracted using Trizol¯ Reagent (Invitrogen, USA),
and RNA was reverse transcribed to single-stranded cDNA using a High Capacity Kit
(Applied Biosystems, USA) according to the manufacturer's protocol. For quantitative
analysis of the genes of interest [pre-pro-AM (Rn 00562327_m1), CRLR (Rn
00562334_m1), RAMP1 (Rn 01427056_m1), RAMP2 (Rn 00824652_m1), and RAMP3 (Rn
00571815_m1)], a commercially available TaqMan Assay-on-Demand System that consists
of a kit of oligonucleotides and probes was used (Applied Biosystems). Reverse
transcription was performed using 1 µg total RNA for each sample in 20 µL of the
total reaction mixture. The cDNA obtained was diluted 1:10, and 4.5 µL was used for
each 10 µL of the qRT-PCR mixture using the TaqMan Master Mix (Applied Biosystems).
Reactions were carried out in duplicate and analyzed with 7500 Sequence Detection
System apparatus (Applied Biosystems). Data were analyzed using the ABI-7500 SDS
software (Applied Biosystems). Total RNA absorbed was normalized on the basis of the
Ct value for the GAPDH gene (Rn 01775763_m1). The variation in expression among
samples was calculated by the 2−ΔΔCt method, and the mean delta Ct value
for a group of six samples from the control was used for calibration (17).
Western immunoblotting
CSM was frozen in liquid nitrogen and homogenized in lysis buffer (50 mM Tris-HCl, pH
7.4, 1% IGEPAL, 0.5% sodium deoxycholate, 1% SDS). Homogenates were centrifuged at
5,000 g for 10 min; the pellet was then discarded, and the
supernatant was stored at −80°C. Sixty micrograms of protein were separated by
electrophoresis on a 10% or 15% polyacrylamide gel and transferred onto a
nitrocellulose membrane. The 15% polyacrylamide gel was used for AM separation.
Nonspecific binding sites were blocked with 7% skim milk in Tris-buffered saline
solution with Tween 20 for 1 h at 24°C. The membranes were then incubated with the
following specific antibodies (Santa Cruz Biotechnology, USA) overnight at 4°C: AM
(sc-16496, 1:250 dilution), CRLR (sc-18007, 1:250), RAMP1 (sc-11379, 1:250), RAMP2
(sc-11380, 1:250), and RAMP3 (sc-11381, 1:250). Beta-actin (sc-1616, 1:2000) was used
as an internal control. After the membranes were incubated with labeled secondary
antibodies, signals were detected by chemiluminescence and visualized by
autoradiography.
Immunohistochemistry
Paraffin-embedded CSM segments were stained using the avidin-biotinylated peroxidase
complex method. Briefly, 4-µm sections (Reichert Jung 2040 microtome, Leica, USA)
were cut, deparaffinized with xylene and dehydrated in ethanol. Endogenous peroxidase
and biotin were blocked by immersing slides in 3% hydrogen peroxide. The sections
were incubated with the following primary antibodies: AM (sc-16496, 1:250) and CRLR
(sc-18007, 1:250). The reactions were revealed using 0.2 mg/mL diaminobenzidine
solution (10 mg tablets in 50 mL PBS 0.01 M, pH 7.4; D5905; Sigma-Aldrich, USA) and
stained by Harris hematoxylin. On each slide, two fields were selected in areas with
high concentrations of positive cells or stained cells, using 50× or 1000×
magnification. The slides were analyzed using a Leica model DM 5500 B microscope. The
images were registered using a Leica digital camera DFC 290 (3MP) attached to the
microscope and filed using the Leica QWin software.
Functional studies
CSM was isolated as described previously (16).
In brief, the penis was harvested by cutting the corporeal body at the level of its
attachment to the ischium bone and then immersed in Krebs solution (130 mM NaCl, 4.7
mM KCl, 1.18 mM KH2PO4, 1.17 mM
MgSO4.7H2O, 1.6 mM CaCl2.2H2O, 14.9 mM
NaHCO3, and 5.5 mM glucose). The tunica albuginea was carefully opened
from its proximal extremity toward the penile shaft, and the erectile tissue within
the corpus cavernosum was surgically dissected free. Strips of CSM (1×1×10 mm) were
mounted in a 5-mL organ chamber containing Krebs solution at 37°C and continuously
bubbled with a gas mixture of 95% oxygen and 5% carbon dioxide, pH 7.4. One end of
each corporal strip was attached to the bottom of the organ bath and the other end
was tied to a force transducer (TRI201, Panlab, Spain). The strips were stretched to
a resting tension of 3 mN and allowed to equilibrate for 60 min. The responses were
recorded on a computer system using Chart Pro 5 (PowerLab, ADInstruments,
Australia).CSM strips were precontracted with phenylephrine (10 µM), and when the contraction
reached a plateau, concentration-response curves for AM (10 fM to 30 nM) were
obtained by stepwise increase of the agonist concentration. Additions were made as
soon as a steady response was obtained from the preceding concentration. For
comparison, concentration-response curves for CGRP (1 pM to 0.3 µM) and acetylcholine
(1 nM to 1 mM) were also obtained in precontracted CSM strips. Relaxation is reported
as the percent change from phenylephrine-contracted levels.The mechanisms underlying AM-induced relaxation were evaluated by experiments
performed in the presence of 100 µM NG-nitro-L-arginine-methyl-ester
[L-NAME, a nonselective NO synthase (NOS) inhibitor], 100 µM 7-nitroindazole [a
selective neuronal NOS (nNOS) inhibitor], 1 µM
1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, selective guanylyl cyclase
inhibitor), 3 µM Rp-8-Br-PET-cGMPS (cGMP-dependent protein kinase inhibitor), 10 µM
sildenafil (phosphodiesterase 5 inhibitor), 1 µM wortmannin (phosphatidylinositol
3-kinase inhibitor), 10 µM SC560 (selective cyclooxygenase-1 inhibitor), 1 mM
4-aminopyridine (selective blocker of voltage-dependent K+ channels), 1 μM
apamin (selective blocker of low-conductance Ca2+-activated channels), 3
μM glibenclamide (selective blocker of ATP-sensitive K+ channels), 100 μM
SQ22536 (adenylate cyclase inhibitor), 1 μM H89 (cAMP-dependent protein kinase
inhibitor), 0.01-1 µM AM22-52 (AM receptor antagonist), or 0.1 µM
CGRP8-37 (CGRP receptor antagonist). All drugs were incubated for 30
min. Drug concentrations were selected from the literature (18-23). The agonist
concentration-response curves were fitted using a nonlinear interactive fitting
program (GraphPad Prism 3.0; GraphPad Software Inc., USA). Agonist potencies and
maximal responses are reported as pD2 (negative logarithm of the molar
concentration of agonist producing 50% of the maximal response) and Emax
(maximum effect elicited by the agonist), respectively.
Nitrate measurements
Nitrate (NO3
−, a metabolite of NO) levels were measured in supernatants from CSM
homogenates. The strips were contracted with 10 µM phenylephrine and then exposed to
30 nM AM or 100 µM L-NAME. Some strips were incubated with 100 µM L-NAME for 30 min
prior to the administration of AM. When the maximal relaxation induced by AM was
achieved, tissues were frozen in liquid nitrogen. CSM was homogenized in 200 µL PBS
buffer, pH 7.4, and centrifuged at 10,000 g (10 min, 4°C). The
supernatant was ultrafiltered (Amicon Ultra-0.5 mL 10 kDa, Millipore, USA) at 14,000
g (15 min, 25°C). A commercially available kit (#780001, Cayman,
USA) was used to measure nitrate levels. Results are reported as μM/mg protein.
Protein concentrations were determined with a protein assay reagent (Bio-Rad
Laboratories, USA).
6-keto-PGF1α measurements
6-keto-PGF1α, a stable hydrolyzed product of unstable prostacyclin
(PGI2), was measured in CSM homogenates. The strips were contracted
with 10 µM phenylephrine and were then exposed to 30 nM AM. When the maximal
relaxation induced by AM was achieved, the strips were frozen in liquid nitrogen. CSM
was homogenized in EIA buffer (1 M phosphate solution containing 1% BSA, 4 M sodium
chloride, 10 mM EDTA and 0.1% sodium azide) and centrifuged at 2000
g (15 min, 4°C). The samples (50 µL) were deproteinized by
precipitation using 50 µL absolute ethanol kept at 4°C, followed by stirring and then
kept for 30 min in a freezer at -20°C. The supernatant was centrifuged at 4000
g (10 min, 25°C). Levels of 6-keto-PGF1α were measured
using a commercially available kit (Cayman, code 515211). Results are reported as
pg/mg protein. Protein concentrations were determined with a protein assay reagent
(Bio-Rad Laboratories).
Drugs
ODQ, 7-nitroindazole, SC560, and glibenclamide were prepared as stock solutions in
dimethyl sulfoxide (DMSO), whereas the other drugs were dissolved in distilled water.
The bath concentration of DMSO did not exceed 0.5%, which was shown to have no
effects per se on basal tonus of the preparations or on
agonist-mediated relaxation.
Statistical analysis
Data are reported as means±SE. Statistically significant differences were determined
by the Student t-test or analysis of variance (ANOVA) followed by
the Bonferroni multiple comparison test. P<0.05 was considered to be statistically
significant.
Results
Protein and mRNA expression of AM system components in rat CSM
Figure 1A shows representative immunoblots for
AM, CRLR, and RAMP1, -2, and -3 protein expression in rat CSM. The results obtained
by qRT-PCR showed that rat CSM expressed mRNA of pre-pro-AM, CRLR, and RAMP1, -2, and
-3 (Figure 1B).
Figure 1
Protein and mRNA expression of AM system components in the rat CSM.
A, Representative immunoblots for AM, CRLR and RAMP1, -2,
-3 protein expression. B, mRNA expression of pre-pro-AM, CRLR
and RAMP1, -2, -3 in the rat CSM was assessed by qRT-PCR. The results are
reported as the expression of the individual mRNAs with normalization to the
housekeeping gene GAPDH by using the Ct method. Data are reported as means±SE
of n=5 to 7 CSM. AM: adrenomedullin; CSM: cavernosal smooth muscle; CRLR:
calcitonin receptor-like receptor; RAMP: receptor activity-modifying
protein.
Expression and localization of AM and CRLR in rat CSM
Immunohistochemical studies revealed staining for AM and CRLR in rat cavernous
tissue. Nuclear staining for both AM and CRLR were detected diffusely in all
constituents of the cavernous tissue including connective tissue, in the
endothelium lining vascular spaces, and in smooth muscle (Figure 2).
Figure 2
Representative immunohistochemical photomicrographs of adrenomedullin
(AM) and calcitonin receptor-like receptor (CRLR) in rat cavernosal smooth
muscle sections. AM (A) and CRLR (B)
nuclear staining (arrows on the images in detail) were detected diffusely in
all constituents of the cavernous tissue (CT): connective tissue,
endothelium lining the vascular spaces and in smooth muscle. A: tunica
albuginea; C: corpora cavernosa; E: spongy body; VS: vascular spaces; U:
urethra. Magnification 50× and 1000× (inset).
Mechanisms underlying the relaxant effect induced by AM in isolated CSM
strips
AM relaxed rat CSM strips in a concentration-dependent manner (Emax:
53.9±2.5%; pD2: 10.6±0.2, n=6). Similarly, CGRP (Emax:
52.5±6.9%; pD2: 10.0±0.2, n=6) and acetylcholine (Emax:
54.7±2.3%; pD2: 6.8±0.2, n=5) relaxed CSM strips (Figure 3). The maximal relaxation induced by the agonists was
of similar magnitude. However, AM and CGRP were more potent than acetylcholine at
inducing CSM relaxation (P<0.05, ANOVA).
Figure 3
Concentration-response curves for AM, CGRP, and acetylcholine obtained
in isolated rat cavernosal smooth muscle strips. The curves were obtained in
CSM pre-contracted with phenylephrine (10 µM). Data are reported as means±SE
of 5 to 6 independent preparations. AM: adrenomedullin; CGRP: calcitonin
gene-related peptide.
In order to verify the mechanisms underlying AM-induced relaxation, CSM strips
were exposed to a variety of drugs. AM22-52, a selective antagonist for
AM receptors, reduced the maximal relaxation induced by AM in isolated rat CSM.
The relaxation induced by AM (Emax: 53.9±2.5%; pD2:
10.9±0.3, n=6) was significantly reduced (P<0.05, ANOVA) in the presence of
AM22-52 at concentrations of 0.1 µM (Emax: 38.3±3.9%;
pD2: 10.8±0.4, n=6), 0.3 µM (Emax: 31.9±1.9%;
pD2: 10.8±0.2, n=6) and 1 µM (Emax: 20.4±0.9%;
pD2: 10.6±0.2, n=6) (Figure
4). At the concentration of 0.01 µM, AM22-52 did not affect
AM-induced relaxation (Emax: 43.8±1.5%; pD2: 10.5±0.1, n=6).
Similarly, CGRP8-37 (Emax: 44.1±1.8%; pD2:
10.6±0.3, n=6) did not alter the relaxation induced by AM (Figure 4). Neither H89 (Emax: 49.7±7.7%;
pD2: 11.1±0.4, n=5) nor SQ22536 (Emax: 51.6±1.8%;
pD2: 11.4±0.2, n=5) altered AM-induced relaxation (Figure 5). L-NAME, ODQ, Rp-8-Br-PET-cGMPS, and
SC560 reduced AM-induced relaxation to a similar extent (Figure 6, Table 1).
The combination of L-NAME and SC560 showed further suppression of AM relaxation
than that observed with either L-NAME or SC560 alone. However, even when combined,
these compounds were not able to abolish AM-induced relaxation. Sildenafil induced
a leftward displacement in the concentration-response curve for AM. Conversely,
7-nitroindazole and wortmannin did not alter the relaxation induced by AM (Figure 6, Table 1). 4-Aminopyridine, but not apamin or glibenclamide, reduced the
relaxation induced by AM in rat CSM (Figure
7, Table 1).
Figure 4
Concentration-response curves for AM obtained in rat cavernosal smooth
muscle strips in the absence or presence of 0.01-1 µM AM22-52 and
0.1 µM CGRP8-37. Data are reported as means±SE of 5 to 6
independent preparations. AM: adrenomedullin; CGRP: calcitonin gene-related
peptide.
Figure 5
Relaxation responses induced by adrenomedullin (AM) on rat cavernosal
smooth muscle strips pre-contracted with phenylephrine. The
concentration-response curves were obtained in the absence (control) or
after incubation for 30 min with 100 μM SQ22536 (top) or 1
μM H89 (bottom). Data are reported as means±SE of 5
independent preparations.
Figure 6
Relaxation responses induced by adrenomedullin (AM) on rat cavernosal
smooth muscle strips pre-contracted with phenylephrine. The
concentration-response curves were obtained in the absence (control) or
after incubation for 30 min with the following drugs: 100 µM L-NAME, 100 µM
7-nitroindazole, 1 µM ODQ, 3 µM Rp-8-Br-PET-cGMPS, 10 µM sildenafil, 1 µM
wortmannin, 10 µM SC560, or the combination of L-NAME and SC560. Data are
reported as means±SE of 5 to 6 independent preparations.
Figure 7
Relaxation responses induced by adrenomedullin (AM) on rat cavernosal
smooth muscle strips pre-contracted with phenylephrine. The
concentration-response curves were obtained in the absence (control) or
after incubation for 30 min with 3 µM glibenclamide, 1 µM apamin, or 1 mM
4-aminopyridine. Data are reported as means±SE of 5 to 6 independent
preparations.
Nitrate and 6-keto-PGF1α measurements
AM significantly increased 6-keto-PGF1α (a stable product of
PGI2) in rat CSM compared with tissues that were not stimulated with
the peptide (Figure 8A). AM significantly
increased nitrate generation in rat CSM compared with tissues that were not
stimulated with the peptide (Figure 8B).
AM-induced nitrate generation was significantly inhibited by L-NAME, which had no
effect per se on basal nitrate levels.
Figure 8
6-keto-PGF1α and nitrate levels in rat cavernosal smooth muscle
strips stimulated with adrenomedullin (AM). Data are reported as means±SE of 5
to 6 independent preparations. *P<0.05, compared to basal (Student
t-test); #P<0.05, compared to basal, L-NAME,
and AM+L-NAME (ANOVA followed by the Bonferroni multiple comparison
test).
Discussion
In the present study, protein and mRNA expression of AM, CRLR, and RAMP1, -2, and -3
were detected in rat CSM. Immunohistochemical assays showed that AM and CRLR are
expressed in the cavernous tissue. AM acts as a circulating hormone and locally in an
autocrine/paracrine fashion. Because AM is expressed in rat CSM, it may play a role in
the autocrine/paracrine regulation of penile erection due to its vasodilator action. AM
is considered an important regulatory peptide that helps to regulate cardiovascular
homeostasis. AM levels in cardiovascular tissues are elevated to compensate for changes
induced by cardiovascular diseases such as atherosclerosis and hypertension (24). Thus, increased AM expression in CSM could
exert a protective action against ED. In fact, it has been suggested that combination
therapy using PGE1 and proerection agents such as AM may be beneficial in the
treatment of ED (25).A pharmacological characterization of the mechanisms mediating the relaxant effect of AM
in rat CSM was attempted with functional assays, using standard muscle bath procedures.
AM induced CSM relaxation in a concentration-dependent manner. AM was similar in potency
to CGRP, and both were more potent than acetylcholine, which is in accordance with
previous findings in rat aorta (26), rat
mesenteric arterial bed (27), and cat CSM (6). Relaxation induced by AM has been previously
described in isolated rabbit CSM in a concentration range different from that employed
in the present study (11). A possible explanation
for such discrepancy is that the mechanism by which AM induces vasorelaxation or
erection varies with species, vascular bed studied, and experimental procedure employed
(5-7,11,28).The AM receptor is composed of the CRLR and specific RAMP (9,10). RAMPs are a class of
type I transmembrane proteins that interact with and modulate the activities of G
protein-coupled receptors. Cell surface RAMP2-CRLR and RAMP3-CRLR complexes are AM
receptors, while the RAMP1-CRLR complex forms the CGRP receptor (9,10). RAMP interaction with
its associated receptor can lead to three potential consequences: trafficking of
receptor protein from an intracellular compartment to the cell surface, alteration in
the terminal glycosylation of the receptor, and alteration of receptor phenotype,
presumably through a direct or indirect effect on the ligand-binding site (29). Although the antagonist AM22-52 has
been shown to selectively inhibit AM receptors, CGRP8-37 is a CGRP receptor
antagonist that has been shown to be able to block some, but not all, of the actions of
AM in the vasculature (30). This observation
indicates that the vasorelaxation induced by AM may occur due to its interaction with
both AM or CGRP receptors. The present findings show that AM-induced CSM relaxation was
attenuated by AM22-52, but not CGRP8-37. Our study provides the
first functional evidence that relaxation induced by AM in rat CSM is solely mediated by
AM receptors.Activation of adenylate cyclase with consequent increase in cAMP and cAMP-dependent
protein kinase activation has been implicated in the vascular relaxation induced by AM
(31,32). In our study, neither SQ22536 nor H89 altered AM-induced relaxation, which
is not consistent with the participation of adenylate cyclase and protein kinase in this
response.In some vascular tissues, AM induces relaxation via production of NO, with consequent
increases in cGMP levels (33,34). NO is formed from L-arginine by the catalytic
action of the enzyme NOS. The latter has three isoforms: nNOS (or NOS type I), inducible
NOS (or NOS type II), and endothelial NOS (eNOS or NOS type III). nNOS and eNOS are the
main isoforms involved in penile erection and are present in the nerves and endothelium
of the penis, respectively (35). Our data show
that L-NAME partially, but significantly, reduced AM-mediated relaxation. In addition,
AM increased nitrate levels in rat CSM, and this response was inhibited by L-NAME,
further implicating NOS in this process. Taken together, these results show that
activation of NOS with consequent NO generation play a role in AM-mediated relaxation.
7-Nitroindazole, a selective nNOS inhibitor, had no effect on AM-induced relaxation,
suggesting that this NOS isoform could not account for the AM-mediated relaxation in rat
CSM. The selective inhibitor of guanylyl cyclase enzyme, ODQ, reduced the relaxant
action of AM, confirming the involvement of the NO-cGMP pathway in this response as
previously observed in cat and rat CSM (5-7). cGMP-stimulated protein kinase (PKG) acts
downstream to reduce Ca2+ concentration and/or the sensitivity of the
contractile proteins to Ca2+, thus leading to smooth muscle relaxation. Our
findings show that PKG activation plays a role in AM-induced relaxation because
Rp-8-Br-PET-cGMPS reduced this response. Phosphodiesterase type 5 (PDE5) is widely
expressed in CSM, where it catalyzes cGMP hydrolysis (36). Sildenafil, a PDE5 inhibitor, induced a leftward displacement of the
concentration-response curves for AM, further suggesting that PDE5 negatively modulates
the relaxation induced by AM.AM has also been shown to elicit phosphatidylinositol 3-kinase (PI3K) activation and Akt
phosphorylation, resulting in the stimulation of eNOS (37). Our findings with wortmannin discard the participation of the PI3K/Akt
pathway on AM-induced relaxation. It is important to note that blockade of the NO-cGMP
pathway only partially attenuated the relaxant response induced by AM, indicating that
mediators unrelated to the production of NO also participate in this response. In fact,
we observed that the relaxation evoked by AM was partially blunted by SC560, an
inhibitor of cyclooxygenase-1, suggesting the involvement of vasodilator prostanoids in
the relaxing effect of AM. Additionally, AM increased 6-keto-PGF1α, a stable
product of PGI2. These results agree with a previous finding showing the
participation of prostanoids in AM-induced relaxation in porcine ciliary arteries (38). When L-NAME and SC560 were simultaneously added
to the organ bath, an additional inhibitory effect on AM-induced relaxation was
observed, indicating that both NO and vasodilator prostanoids participate in this
response.Activation of K+ channels is an important mechanism in vascular smooth muscle
hyperpolarization and relaxation, and cGMP can modulate the activity of K+
channels to elicit vasodilatation. A role for K+ channels in AM-mediated
relaxation has already been described for vasculature (27,38). We found that 4-aminopyridine,
but not glibenclamide or apamin, reduced AM-induced relaxation, indicating that the
activation of voltage-sensitive K+ channels plays a role in such
responses.The major new finding of the present study is that AM receptors mediate CSM relaxation
via the NO-cGMP pathway, vasodilator prostanoids (probably PGI2), and the
opening of K+ channels. Studies of the expression and function of AM
receptors in CSM may provide valuable information on the contribution of AM to CSM tone,
since this tissue is a useful model for the study of penile erectile responses and
ED.
Authors: Ulisses V Hipólito; Juliana T Rocha; Alisson Martins-Oliveira; Daniela P C Tirapelli; Ana Jacob-Ferreira; Marcelo E Batalhão; José E Tanus-Santos; Evelin C Carnio; Thiago M Cunha; Regina H Queiroz; Carlos R Tirapelli Journal: Alcohol Date: 2011-08-06 Impact factor: 2.405
Authors: Fermino S Lizarte; Marcelo Morgueti; Carlos R Tirapelli; Mario A Claudino; Paulo R B Evora; Paulo C Novais; Daniela P C Tirapelli; Andrea C Celotto; Verena K Capellini; Fabia P M Celini; Silvio Tucci; Adauto J Cologna; Edson Antunes; Antonio C P Martins; Luis F Tirapelli Journal: BJU Int Date: 2010-02-02 Impact factor: 5.588
Authors: David H W Lau; Sashi Kommu; Faiz H Mumtaz; Robert J Morgan; Cecil S Thompson; Dimitri P Mikhailidis Journal: Curr Vasc Pharmacol Date: 2006-04 Impact factor: 2.719
Authors: Y Hirata; H Hayakawa; Y Suzuki; E Suzuki; H Ikenouchi; O Kohmoto; K Kimura; K Kitamura; T Eto; K Kangawa Journal: Hypertension Date: 1995-04 Impact factor: 10.190